{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:01:25Z","timestamp":1751774485337,"version":"3.41.0"},"reference-count":30,"publisher":"The Fukushima Society of Medical Science","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2025]]},"DOI":"10.5387\/fms.24-00054","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:06:19Z","timestamp":1743113179000},"page":"195-201","source":"Crossref","is-referenced-by-count":1,"title":["Successful treatment of rheumatoid arthritis complicated by anti-Jo-1 antibody-positive myopathy with abatacept: A case report"],"prefix":"10.5387","volume":"71","author":[{"given":"Shuhei","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Temmoku","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ohta Nishinouchi General Hospital Foundation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ohta Nishinouchi General Hospital Foundation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Sumichika","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine"},{"name":"Department of Rheumatology, St. Francis Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3342","reference":[{"unstructured":"1.  Kolarz K, Targo\u0144ska-St\u0119pniak B, Majdan M. [Early reumatoid arthritis]. Wiad Lek, <b>71<\/b>:1061-1065, 2018.","key":"1"},{"doi-asserted-by":"crossref","unstructured":"2.  Fern\u00e1ndez-D\u00edaz C, Atienza-Mateo B, Casta\u00f1eda S, <i>et al.<\/i> Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients. Rheumatology (Oxford), <b>61<\/b>:299-308, 2021.","key":"2","DOI":"10.1093\/rheumatology\/keab317"},{"doi-asserted-by":"crossref","unstructured":"3.  Ost\u00f6r AJ. Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Clin Rheumatol, <b>27<\/b>:1343-1353, 2008.","key":"3","DOI":"10.1007\/s10067-008-0964-3"},{"doi-asserted-by":"crossref","unstructured":"4.  \u00c7a\u011flayan M, I\u015fik H, Oktayoglu P. A Case of Refractory Polymyositis Successfully Treated With Abatacept Monotherapy. Arch Rheumatol, <b>35<\/b>:618-622, 2020.","key":"4","DOI":"10.46497\/ArchRheumatol.2020.7406"},{"doi-asserted-by":"crossref","unstructured":"5.  Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis\u2014a case-based review. Clin Rheumatol, <b>34<\/b>:609-612, 2015.","key":"5","DOI":"10.1007\/s10067-014-2507-4"},{"doi-asserted-by":"crossref","unstructured":"6.  Tj\u00e4rnlund A, Tang Q, Wick C, <i>et al.<\/i> Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis, <b>77<\/b>:55-62, 2018.","key":"6","DOI":"10.1136\/annrheumdis-2017-211751"},{"doi-asserted-by":"crossref","unstructured":"7.  Mohammed MJ, Hashim HT, Al-Obaidi AD, Al Shammari A. A novel overlap syndrome: Rheumatoid arthritis, Sjogren\u2019s syndrome, antiphospholipid syndrome, and dermatomyositis. Clin Case Rep, <b>11<\/b>:e7274, 2023.","key":"7","DOI":"10.1002\/ccr3.7274"},{"doi-asserted-by":"crossref","unstructured":"8.  Weerasinghe WS, Jayasinghe C. Overlapping rheumatoid arthritis and antisynthetase syndrome with secondary Sj\u00f6gren\u2019s syndrome: a case report and review of the literature. J Med Case Rep, <b>16<\/b>:132, 2022.","key":"8","DOI":"10.1186\/s13256-022-03353-3"},{"doi-asserted-by":"crossref","unstructured":"9.  Lundberg IE, Tj\u00e4rnlund A, Bottai M, <i>et al.<\/i> 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis, <b>76<\/b>:1955-1964, 2017.","key":"9","DOI":"10.1136\/annrheumdis-2017-212786"},{"doi-asserted-by":"crossref","unstructured":"10.  Hossen MM, Ma Y, Yin Z, <i>et al.<\/i> Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol, <b>14<\/b>:1198365, 2023.","key":"10","DOI":"10.3389\/fimmu.2023.1198365"},{"doi-asserted-by":"crossref","unstructured":"11.  Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood, <b>131<\/b>:58-67, 2018.","key":"11","DOI":"10.1182\/blood-2017-06-741033"},{"doi-asserted-by":"crossref","unstructured":"12.  Kremer JM, Westhovens R, Leon M, <i>et al.<\/i> Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med, <b>349<\/b>:1907-1915, 2003.","key":"12","DOI":"10.1056\/NEJMoa035075"},{"doi-asserted-by":"crossref","unstructured":"13.  Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford), <b>53<\/b>:397-405, 2014.","key":"13","DOI":"10.1093\/rheumatology\/ket279"},{"doi-asserted-by":"crossref","unstructured":"14.  Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol, <b>7<\/b>:297-306, 2011.","key":"14","DOI":"10.1038\/nrrheum.2011.39"},{"doi-asserted-by":"crossref","unstructured":"15.  Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol, <b>8<\/b>:656-664, 2012.","key":"15","DOI":"10.1038\/nrrheum.2012.153"},{"doi-asserted-by":"crossref","unstructured":"16.  Oddis CV, Medsger TA, Jr., Cooperstein LA. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis\/dermatomyositis. Arthritis Rheum, <b>33<\/b>:1640-1645, 1990.","key":"16","DOI":"10.1002\/art.1780331106"},{"doi-asserted-by":"crossref","unstructured":"17.  Meyer O, Charlanne H, Cherin P, <i>et al.<\/i> Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome. Ann Rheum Dis, <b>68<\/b>:152-153, 2009.","key":"17","DOI":"10.1136\/ard.2007.078907"},{"doi-asserted-by":"crossref","unstructured":"18.  Mumm GE, McKown KM, Bell CL. Antisynthetase syndrome presenting as rheumatoid-like polyarthritis. J Clin Rheumatol, <b>16<\/b>:307-312, 2010.","key":"18","DOI":"10.1097\/RHU.0b013e3181f3bf9c"},{"doi-asserted-by":"crossref","unstructured":"19.  Matsushita M, Tamura N, Ogasawara M, Tada K, Yamaji K, Takasaki Y. The Association of Anti-Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibodies in Patients With Rheumatoid Arthritis and Interstitial Lung Disease. Arch Rheumatol, <b>33<\/b>:26-32, 2018.","key":"19","DOI":"10.5606\/ArchRheumatol.2018.6401"},{"doi-asserted-by":"crossref","unstructured":"20.  Kelly CA, Saravanan V, Nisar M, <i>et al.<\/i> Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics\u2014a large multicentre UK study. Rheumatology (Oxford), <b>53<\/b>:1676-1682, 2014.","key":"20","DOI":"10.1093\/rheumatology\/keu165"},{"doi-asserted-by":"crossref","unstructured":"21.  Kiely P, Busby AD, Nikiphorou E, <i>et al.<\/i> Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open, <b>9<\/b>:e028466, 2019.","key":"21","DOI":"10.1136\/bmjopen-2018-028466"},{"doi-asserted-by":"crossref","unstructured":"22.  Raimundo K, Solomon JJ, Olson AL, <i>et al.<\/i> Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. J Rheumatol, <b>46<\/b>:360-369, 2019.","key":"22","DOI":"10.3899\/jrheum.171315"},{"doi-asserted-by":"crossref","unstructured":"23.  Hyldgaard C, Hilberg O, Pedersen AB, <i>et al.<\/i> A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis, <b>76<\/b>:1700-1706, 2017.","key":"23","DOI":"10.1136\/annrheumdis-2017-211138"},{"doi-asserted-by":"crossref","unstructured":"24.  Restrepo JF, del Rinc\u00f3n I, Battafarano DF, Haas RW, Doria M, Escalante A. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol, <b>34<\/b>:1529-1536, 2015.","key":"24","DOI":"10.1007\/s10067-015-3025-8"},{"doi-asserted-by":"crossref","unstructured":"25.  Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum, <b>43<\/b>:613-626, 2014.","key":"25","DOI":"10.1016\/j.semarthrit.2013.09.005"},{"unstructured":"26.  Smolen JS, Landew RBM, Bijlsma JWJ, <i>et al.<\/i> EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis, <b>79<\/b>:685-699, 2020.","key":"26"},{"unstructured":"27.  Singh JA, Saag KG, Bridges SL, Jr., <i>et al.<\/i> 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol, <b>68<\/b>:1-26, 2016.","key":"27"},{"doi-asserted-by":"crossref","unstructured":"28.  Holroyd CR, Seth R, Bukhari M, <i>et al.<\/i> The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford), <b>58<\/b>:e3-e42, 2019.","key":"28","DOI":"10.1093\/rheumatology\/key208"},{"doi-asserted-by":"crossref","unstructured":"29.  Tardella M, Di Carlo M, Carotti M, Ceccarelli L, Giovagnoni A, Salaffi F. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. Inflammopharmacology, <b>30<\/b>:705-712, 2022.","key":"29","DOI":"10.1007\/s10787-022-00936-w"},{"doi-asserted-by":"crossref","unstructured":"30.  Tsujii A, Isoda K, Yoshimura M, <i>et al.<\/i> Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study. BMC Rheumatol, <b>8<\/b>:4, 2024.","key":"30","DOI":"10.1186\/s41927-024-00374-x"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/71\/3\/71_24-00054\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:46:00Z","timestamp":1751690760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/71\/3\/71_24-00054\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.24-00054","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"type":"print","value":"0016-2590"},{"type":"electronic","value":"2185-4610"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"24-00054"}}